- Home
- TNGX vs NAGE Comparison
TNGX vs NAGE Comparison
Compare TNGX & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- NAGE
- Stock Information
- Founded
- TNGX 2014
- NAGE 1999
- Country
- TNGX United States
- NAGE United States
- Employees
- TNGX N/A
- NAGE N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- NAGE Medicinal Chemicals and Botanical Products
- Sector
- TNGX Health Care
- NAGE Health Care
- Exchange
- TNGX Nasdaq
- NAGE Nasdaq
- Market Cap
- TNGX 723.2M
- NAGE 766.4M
- IPO Year
- TNGX N/A
- NAGE N/A
- Fundamental
- Price
- TNGX $7.58
- NAGE $7.26
- Analyst Decision
- TNGX Strong Buy
- NAGE Strong Buy
- Analyst Count
- TNGX 6
- NAGE 3
- Target Price
- TNGX $10.00
- NAGE $17.00
- AVG Volume (30 Days)
- TNGX 2.6M
- NAGE 1.1M
- Earning Date
- TNGX 11-05-2025
- NAGE 10-30-2025
- Dividend Yield
- TNGX N/A
- NAGE N/A
- EPS Growth
- TNGX N/A
- NAGE N/A
- EPS
- TNGX N/A
- NAGE 0.22
- Revenue
- TNGX $24,296,000.00
- NAGE $116,303,000.00
- Revenue This Year
- TNGX $20.42
- NAGE $28.91
- Revenue Next Year
- TNGX N/A
- NAGE $20.89
- P/E Ratio
- TNGX N/A
- NAGE $33.73
- Revenue Growth
- TNGX N/A
- NAGE 35.90
- 52 Week Low
- TNGX $1.03
- NAGE $3.18
- 52 Week High
- TNGX $8.80
- NAGE $14.69
- Technical
- Relative Strength Index (RSI)
- TNGX 51.87
- NAGE 29.31
- Support Level
- TNGX $7.66
- NAGE $6.82
- Resistance Level
- TNGX $8.80
- NAGE $10.06
- Average True Range (ATR)
- TNGX 0.51
- NAGE 0.58
- MACD
- TNGX -0.04
- NAGE -0.30
- Stochastic Oscillator
- TNGX 33.70
- NAGE 11.89
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.